Alnylam Receives Undisclosed Milestone from Roche Under RNAi Rx Collaboration

The companies first began working together in 2007. Under that agreement, Roche acquired a non-exclusive license to use Alnylam's fundamental RNAi intellectual property to develop therapeutics in oncology, respiratory diseases, metabolic diseases, and certain liver diseases.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.